Literature DB >> 21811875

The association between non-Hodgkin lymphoma and methylation of p73.

Jing-Hong Pei1, Sai-Qun Luo, Yan Zhong, Jiang-Hua Chen, Hua-Wu Xiao, Wei-Xin Hu.   

Abstract

To investigate the effects of methylation of the p73 gene on the pathogenesis of non-Hodgkin lymphoma (NHL), the methylation status of the p73 gene promoter and the expression of p73 mRNA were examined in NHLs by methylation-specific polymerase chain reaction (MSP) and reverse transcription-polymerase chain reaction, respectively; p73 protein was detected by Western blotting analysis. Furthermore, the expression of p73 mRNA in NHL cells treated with 5-Aza-2'-deoxycytidine was analyzed. MSP results revealed that the promoter of p73 was methylated in 87.5% of NHLs but was not methylated in reactive hyperplasia lymph node samples. The expression of p73 mRNA was not detected in 83.33% of NHLs but was detected in all of the reactive hyperplasia lymph node samples. The p73 protein was not detected in 91.67% of NHLs but was detected in all of the reactive hyperplasia lymph node samples. The expression of p73 mRNA was detected in NHL cells treated with 5-Aza-2'-deoxycytidine. The inactivation of p73, predominantly by methylation, may be involved in the pathogenesis of NHLs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21811875     DOI: 10.1007/s13277-011-0215-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation.

Authors:  M Liu; T Taketani; R Li; J Takita; T Taki; H W Yang; H Kawaguchi; K Ida; Y Matsuo; Y Hayashi
Journal:  Leuk Res       Date:  2001-06       Impact factor: 3.156

2.  Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.

Authors:  Marleen Kok; Johannes M Bonfrer; Catharina M Korse; Daphne de Jong; Marie José Kersten
Journal:  Tumour Biol       Date:  2003 Jan-Feb

Review 3.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 4.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

5.  An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.

Authors:  P W Wijermans; M Lübbert; G Verhoef; V Klimek; A Bosly
Journal:  Ann Hematol       Date:  2005-12       Impact factor: 3.673

6.  DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

Authors:  Allen S Yang; Ketan D Doshi; Sang-Woon Choi; Joel B Mason; Rajan K Mannari; Vazganush Gharybian; Rene Luna; Asif Rashid; Lanlan Shen; Marcos R H Estecio; Hagop M Kantarjian; Guillermo Garcia-Manero; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 7.  The epidemiology of non-Hodgkin's lymphoma.

Authors:  Susan G Fisher; Richard I Fisher
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

8.  Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia.

Authors:  Jose Roman-Gomez; Antonio Jimenez-Velasco; Juan A Castillejo; Xabier Agirre; Manuel Barrios; German Navarro; Francisco J Molina; Maria J Calasanz; Felipe Prosper; Anabel Heiniger; Antonio Torres
Journal:  Blood       Date:  2004-06-15       Impact factor: 22.113

9.  p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.

Authors:  Petra A Link; Maria R Baer; Smitha R James; David A Jones; Adam R Karpf
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 10.  p73: a chiaroscuro gene in cancer.

Authors:  Mirko Marabese; Faina Vikhanskaya; Massimo Broggini
Journal:  Eur J Cancer       Date:  2007-04-10       Impact factor: 9.162

View more
  8 in total

1.  Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line.

Authors:  Kaishan Liu; Wenyan Huang; Weisong Gao; Wenfang He
Journal:  Oncol Lett       Date:  2015-02-26       Impact factor: 2.967

2.  Tumor suppressors p53, p63TAα, p63TAy, p73α, and p73β use distinct pathways to repress telomerase expression.

Authors:  Yuan Yao; Marcia Bellon; Shary N Shelton; Christophe Nicot
Journal:  J Biol Chem       Date:  2012-04-10       Impact factor: 5.157

3.  Lack of association between IL-4 -588C>T polymorphism and NHL susceptibility.

Authors:  Zihan Sun; Jing Pei; Fengyun Cui; Yanhua Jing; Chengjin Hu
Journal:  Tumour Biol       Date:  2014-01-26

4.  Association between interleukin-4 -590C > T polymorphism and non-Hodgkin's lymphoma risk.

Authors:  Cuiling Zhou; Shouyong Cui; Rongjiao Zhou; Lianfeng Dou
Journal:  Tumour Biol       Date:  2013-11-23

Review 5.  Mouse models for efficacy testing of agents against radiation carcinogenesis—a literature review.

Authors:  Leena Rivina; Robert Schiestl
Journal:  Int J Environ Res Public Health       Date:  2012-12-27       Impact factor: 3.390

6.  p73 expression is associated with cellular chemosensitivity in human non-small cell lung cancer cell lines.

Authors:  Kaishan Liu; Xiaomei Zhuang; Zhuoying Mai
Journal:  Oncol Lett       Date:  2012-11-19       Impact factor: 2.967

7.  The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines.

Authors:  Sai-Qun Luo; Jing-Ping Hu; Qiang Qu; Jiang Li; Wei Ren; Jia-Ming Zhang; Yan Zhong; Wei-Xin Hu
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

Review 8.  Coordinated Dialogue between UHRF1 and DNMT1 to Ensure Faithful Inheritance of Methylated DNA Patterns.

Authors:  Christian Bronner; Mahmoud Alhosin; Ali Hamiche; Marc Mousli
Journal:  Genes (Basel)       Date:  2019-01-18       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.